Silvan Tuerkcan
Stock Analyst at JMP Securities
(1.39)
# 3,312
Out of 4,840 analysts
168
Total ratings
34.78%
Success rate
-11.7%
Average return
Main Sectors:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | Reiterates: Market Outperform | $86 | $37.57 | +128.91% | 15 | May 21, 2025 | |
| PRME Prime Medicine | Maintains: Market Outperform | $10 → $6 | $1.27 | +372.44% | 3 | May 20, 2025 | |
| BNTC Benitec Biopharma | Reiterates: Market Outperform | $20 | $14.20 | +40.85% | 12 | May 15, 2025 | |
| FHTX Foghorn Therapeutics | Reiterates: Market Outperform | $9 | $4.03 | +123.33% | 3 | May 15, 2025 | |
| VOR Vor Biopharma | Downgrades: Market Perform | $6 | $0.17 | +3,358.21% | 12 | May 9, 2025 | |
| ENGN enGene Holdings | Reiterates: Market Outperform | $18 | $4.00 | +350.00% | 4 | Apr 29, 2025 | |
| TSHA Taysha Gene Therapies | Reiterates: Market Outperform | $5 | $2.61 | +91.94% | 12 | Apr 28, 2025 | |
| NUVB Nuvation Bio | Initiates: Market Outperform | $6 | $2.24 | +167.86% | 1 | Apr 23, 2025 | |
| TERN Terns Pharmaceuticals | Reiterates: Market Outperform | $20 | $3.01 | +564.45% | 12 | Apr 21, 2025 | |
| EXEL Exelixis | Reiterates: Market Outperform | $41 | $43.09 | -4.85% | 21 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $17 | $1.10 | +1,445.45% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $7 | $0.31 | +2,191.33% | 7 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $0.37 | - | 8 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $15 | $3.04 | +393.42% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $70 | $4.77 | +1,367.51% | 5 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $4 | $0.68 | +487.46% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $2.85 | +636.84% | 10 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.49 | - | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $1.46 | +310.96% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $280 | $299.11 | -6.39% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $18 → $18 | $11.03 | +63.19% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $9.33 | - | 10 | Jan 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $2 → $3 | $8.16 | -63.24% | 3 | May 10, 2022 |
CRISPR Therapeutics AG
May 21, 2025
Reiterates: Market Outperform
Price Target: $86
Current: $37.57
Upside: +128.91%
Prime Medicine
May 20, 2025
Maintains: Market Outperform
Price Target: $10 → $6
Current: $1.27
Upside: +372.44%
Benitec Biopharma
May 15, 2025
Reiterates: Market Outperform
Price Target: $20
Current: $14.20
Upside: +40.85%
Foghorn Therapeutics
May 15, 2025
Reiterates: Market Outperform
Price Target: $9
Current: $4.03
Upside: +123.33%
Vor Biopharma
May 9, 2025
Downgrades: Market Perform
Price Target: $6
Current: $0.17
Upside: +3,358.21%
enGene Holdings
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $4.00
Upside: +350.00%
Taysha Gene Therapies
Apr 28, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $2.61
Upside: +91.94%
Nuvation Bio
Apr 23, 2025
Initiates: Market Outperform
Price Target: $6
Current: $2.24
Upside: +167.86%
Terns Pharmaceuticals
Apr 21, 2025
Reiterates: Market Outperform
Price Target: $20
Current: $3.01
Upside: +564.45%
Exelixis
Apr 17, 2025
Reiterates: Market Outperform
Price Target: $41
Current: $43.09
Upside: -4.85%
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $17
Current: $1.10
Upside: +1,445.45%
Mar 21, 2025
Downgrades: Market Perform
Price Target: $7
Current: $0.31
Upside: +2,191.33%
Mar 14, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $0.37
Upside: -
Mar 7, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $3.04
Upside: +393.42%
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $70
Current: $4.77
Upside: +1,367.51%
Jan 8, 2025
Initiates: Market Outperform
Price Target: $4
Current: $0.68
Upside: +487.46%
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $21
Current: $2.85
Upside: +636.84%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.49
Upside: -
May 31, 2024
Reiterates: Market Outperform
Price Target: $6
Current: $1.46
Upside: +310.96%
Mar 5, 2024
Maintains: Buy
Price Target: $240 → $280
Current: $299.11
Upside: -6.39%
Jan 26, 2023
Maintains: Market Outperform
Price Target: $18 → $18
Current: $11.03
Upside: +63.19%
Jan 19, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $9.33
Upside: -
May 10, 2022
Maintains: Market Outperform
Price Target: $2 → $3
Current: $8.16
Upside: -63.24%